Last edition
News about "biologics formulation innovation"
Alteogen and Biogen Sign Deal for Hybrozyme-Based Subcutaneous Biologics
Alteogen signs a licensing deal with Biogen to develop and commercialise Hybrozyme-based subcutaneous biologics, granting rights for two products using the ALT-B4 platform.
Biologics Formulation Innovation | 26/03/2026 | By News Bureau | 190
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members